Memorial Sloan Kettering Cancer Center | January 13, 2026

Memorial Sloan Kettering Cancer Center | January 13, 2026
[wpb_childpages]

The Future of Melanoma Treatment in 2026

Discussion Highlights:

  • Latest Advances in Frontline Melanoma Treatment: Who should receive which immunotherapy?
  • Options for PD-1 Refractory Melanoma: Best strategies when initial anti-PD-1 treatment fails.
  • Tumor-Infiltrating Lymphocyte (TIL) & Novel Cellular Therapies: Current status and next steps following Lifileucel’s approval.
  • Less Common Melanoma Subtypes: Emerging treatment strategies for Uveal, Mucosal, and Acral melanoma.

Co-Hosts:

  • Dr. Michael Postow, Memorial Sloan Kettering Cancer Center
  • Dr. Alexander Shoushtari, Memorial Sloan Kettering Cancer Center

This is a unique opportunity to hear directly from leading experts in the field and stay informed about the evolving landscape of melanoma care—all from the comfort of your home.